Actively Recruiting
Pharmacogenomic Informed Statin Prescribing
Led by VA Office of Research and Development · Updated on 2026-04-13
410
Participants Needed
2
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins. This gap in patient's use of statins limits the full impact of these effective medications resulting in higher cholesterol levels and CVD risk. The main barriers to using statins are patients' perceived lack of benefit, excess risk of statin toxicity as well as their misperceptions of their CVD risk. Statin pharmacogenomic testing - an application of precision medicine - is a readily available, feasible, and inexpensive intervention that addresses this barrier by using genetic testing to identify the nearly 1 out of 2 patients with enhanced benefit and/or reduced risk of statin toxicity or increased risk for CVD. By communicating statin pharmacogenomic test results to Veterans at high-risk for CVD not taking statin therapy, the investigators aim to improve patients' perceptions of their risk of CVD and statins and, in turn, their acceptance of and adherence to statins to reduce their cholesterol levels and CVD risk.
CONDITIONS
Official Title
Pharmacogenomic Informed Statin Prescribing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be a Veteran
- Be between 40 and 75 years old
- Have diabetes mellitus or cardiovascular disease (coronary, cerebral, or peripheral artery disease)
- Have an upcoming primary care appointment within the next 4 months
- Have no active statin prescription in the past 6 months
- Be able to speak English
- Have at least one current active VA prescription
- Have had at least one primary care appointment within the past 2 years
You will not qualify if you...
- Not be a Veteran
- Have end-stage renal disease
- Have a history of rhabdomyolysis
- Be receiving active treatment for non-dermatologic cancer
- Have known prior SLCO1B1 genetic test results
- Have liver cirrhosis
- Be receiving palliative care or hospice within the past year or during hospital stay or at discharge
- Have an active prescription for PCSK9 inhibitor
- Be unable to provide informed consent due to language impairment, cognitive disease, or similar factors
- Be actively enrolled in a different interventional clinical trial
- Have history of allogeneic stem cell transplant or liver transplant
- Have documented adverse drug reactions attributed to statins such as myopathy with high creatinine kinase, angioedema, elevated AST/ALT, or other reactions at investigator's discretion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Richard L. Roudebush VA Medical Center, Indianapolis, IN
Indianapolis, Indiana, United States, 46202-2884
Actively Recruiting
2
Durham VA Medical Center, Durham, NC
Durham, North Carolina, United States, 27705-3875
Not Yet Recruiting
Research Team
D
Deepak Voora, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here